Excretory–secretory antigens: A suitable candidate for immunization against ocular toxoplasmosis in a murine model

Characterization of Neospora Caninum Microneme Protein 26 and Its Potential Use as a Diagnostic Marker for Neosporosis in Cattle

The apicomplexan parasite Neospora caninum causes neosporosis, an illness that leads to abortion or stillbirth in cattle, causing massive economic losses to the livestock industry. Rapid and viable diagnosis is the premise of prevention and control for neosporosis. In this study, we screened a new microneme protein 26 (NcMIC26) through western blot and mass spectrometry identification from the excretory secretion antigen (ESA) of N. caninum tachyzoites. NcMIC26 is subcellularly localized to the microneme of parasites. NcMIC26 is a specific antigen of N. caninum and has no cross-reaction with Toxoplasma gondii. Therefore, NcMIC26 has the potential to be a candidate diagnostic antigen for neosporosis. To test this hypothesis, recombinant NcMIC26 (rNcMIC26) was expressed in Escherichia coli (E. coli), and an indirect ELISA for detecting anti-N. caninum antibodies in cattle was established. Compared with that of the indirect immunofluorescent antibody test (IFAT), the positive coincidence rate of the ELISA based on rNcMIC26 was 76.53% (75/98), which was higher than that of an ELISA based on rSRS2 (66.33%), and the negative coincidence rate was 84.62% (33/39). It is noteworthy that 30 positive samples confirmed by IFAT were consistent with the rNcMIC26 ELISA but were negative by the rNcSRS2 ELISA. Our research illustrated that NcMIC26 is a dependable diagnostic marker for the serodiagnosis of N. caninum infection in cattle and could be utilized as a supplementary antigen for missed detection by NcSRS2.

IL-17 and IL-22 elicited by a DNA vaccine encoding ROP13 associated with protection against Toxoplasma gondii in BALB/c mice

Toxoplasma gondii, an intracellular parasitic protozoan, is capable of infecting man and all warm-blooded animals. Cell-mediated immunity is vital in mounting protective responses against T. gondii infection. Recent studies have shown that T-helper (Th) 17 responses may play a key role in parasite control. In this current study, we constructed a DNA vaccine encoding T. gondii ROP13 in a pcDNA vector. Groups of BALB/c mice were immunized intramuscularly with pcROP13 or controls and challenged with the RH strain of T. gondii. The results showed that immunization with pcROP13 could elicit an antibody response against T. gondii. The expression of the canonical Th17 cytokines, interleukin (IL)-17 and IL-22, were significantly increased after immunization with pcROP13 compared with control groups ( p < 0.05). Furthermore, vaccination resulted in a significant decrease in parasite load ( p < 0.05). The induction of Th17 related cytokines, using a ROP13 DNA vaccine, against T. gondii should be considered as a potential vaccine approach for the control of toxoplasmosis.

Quantification of Toxoplasma gondii in the tissues of BALB/c mice after immunization with nanoliposomal excretory-secretory antigens using Real-Time PCR

BACKGROUND

Toxoplasmosis is an infectious disease caused by the intracellular parasite Toxoplasma gondii. Although almost 1/3 of the world's population are seropositive, there is no effective vaccine against toxoplasmosis. Therefore, the development of an effective vaccine for control of toxoplasmosis is one of major concerns in parasitology. The aim of this study was to evaluate the efficacy of nano-liposomal excretory-secretory antigens (NLESA) in BALB/c mice.

MATERIALS AND METHODS

Excretory-secretory antigens (ESA) was obtained from tachyzoites, encapsulated in the liposome and studied by scanning electron microscope. BALB/c mice were immunized with NLESA and ESA, sterile phosphate-buffered saline (PBS). Immunization was performed three times at 14-day intervals and challenged with 1 × 10⁴ tachyzoites of T. gondii RH strain four weeks later. The parasite load of mice blood, brain and spleen tissues were determined using quantitative PCR targeted at the repeated element (RE) gene.

RESULTS

The immunization with NLESA and ESA induced a significant increase of anti-Toxoplasma IgG antibody compared with PBS group (P < 0.05). After challenge with tachyzoites, qPCR analyses showed significant reduction of parasite load in NLESA and ESA immunized mice compared with control group (P < 0.05). Also, NLESAs were more effective than ESAs and showed significantly reduced parasite load in blood (P = 0.001) and brain tissue (P = 0.01).

DISCUSSION

The vaccination with NLESA showed more promising results comparing to ESA. Further studies are recommended in order to achieve effectiveness of the vaccine against T. gondii.

Toxoplasma gondii excretory/secretory antigens (TgESAs) suppress pro-inflammatory cytokine secretion by inhibiting TLR-induced NF-κB activation in LPS-stimulated murine macrophages

Excretory/secretory antigens (ESAs) produced by Toxoplasma gondii enable this parasite to invade and survive within the host cells through immunomodulation. In this study, the modulating effects of T. gondii excretory/secretory antigens (TgESAs) on the Ana-1 murine macrophage cell line were evaluated. Ana-1 cells were incubated with several concentrations of TgESAs, and the resulting effects on cellular viability, phagocytotic ability, and apoptosis induction were determined. Pro-inflammatory and anti-inflammatory cytokine secretion, nitric oxide production, toll-like receptor expression, and nuclear translocation of NF-κB were all measured after incubation with TgESAs. After TgESAs treatment, the proliferation and phagocytosis ability of Ana-1 cells decreased, and apoptosis was induced in a dose dependent manner. Analysis of Ana-1 cell culture supernatants showed that TgESAs not only upregulated secretion of anti-inflammatory cytokines (interleukin-10 and transforming growth factor-β1), they also inhibited secretion of pro-inflammatory cytokines (tumor necrosis factor-α and interleukin-1β). Additionally, TgESAs inhibited nitric oxide production, toll-like receptor (TLR) 2 and 4 activation, and the nuclear translocation of NF-κB in lipopolysaccharide-stimulated Ana-1 macrophages. These results suggest TgESAs inhibit the functional activity of Ana-1 murine macrophages by inhibiting TLR-induced NF-κB activation, which suppresses pro-inflammatory cytokine secretion.

Recent advances in developing vaccines against Toxoplasma gondii: an update

Toxoplasma gondii, a significant public health risk, is able to infect almost all warm-blooded animals including humans, and it results in economic losses in production animals. In the last three years, a large number of vaccination experiments have been performed to control T. gondii infection, with the target of limiting the acute infection and reducing or eliminating tissue cysts in the intermediate hosts. In this paper, we summarize the latest results of the veterinary vaccines against T. gondii infection since 2013. Immunization with live-attenuated whole organisms of non-reverting mutants has been shown to induce remarkably potent immune responses associated with control of acute and chronic toxoplasmosis. The non-cyst-forming mutants are promising new tools for the development of veterinary vaccines against T. gondii infection.